BOCA RATON, Fla., July 25, 2017 -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids, with superficial radiation therapy (SRT), announces that management will hold a conference call beginning at 4:30 p.m. Eastern Time on Thursday, August 3, 2017 to discuss the financial results for the second quarter of 2017. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
To access the conference call, the dial-in numbers are 1-877-870-4263 (U.S. Toll Free), 1-412-317-0790 (International) and 1-855-669-9657 (Canada Toll Free). Please direct the operator to be connected to the Sensus Healthcare call.
Following the conclusion of the conference call, a replay will be available through August 10, 2017 and can be accessed by dialing 1-877-344-7529 (U.S. Toll Free), 1-412-317-0088 (International), and 1-855-669-9658 (Canada Toll Free). All listeners should provide the replay passcode 10110870. The call will also be archived on the Company website for a time at https://sensushealthcare.com
About Sensus Healthcare
Sensus Healthcare, Inc. is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy X-ray technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development. Sensus has successfully incorporated SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit https://sensushealthcare.com.
LHA Investor Relations
Kim Sutton Golodetz
View original content:https://www.prnewswire.com/news-releases/sensus-healthcare-to-host-second-quarter-2017-financial-results-and-business-update-conference-call-on-august-3-2017-300493432.html
SOURCE Sensus Healthcare